"Moderna's mRNA Flu Shot Outperforms Current Vaccine in Boosting Immune Response"
Moderna's experimental mRNA-based seasonal flu vaccine, mRNA-1010, has shown a stronger immune response against four strains of the flu virus compared to a currently marketed vaccine in a Phase 3 study. The positive results pave the way for Moderna to discuss a path to approval with regulators. The company is racing against Pfizer to bring mRNA technology to seasonal flu vaccines and plans to combine Covid-19 mRNA shots with flu and RSV vaccines in the future. Moderna expects a decision from the FDA on its mRNA vaccine for RSV in older adults by April. The safety findings of the flu vaccine study were similar to previous ones, with muscle pain, headache, fatigue, pain, and swelling being the most common reactions. The study focused on the immune response generated by the vaccine rather than its efficacy in protecting against flu disease.